Dr. Aung-Din has practiced general neurology and neuro-psychiatry in Sarasota, FL for more than 25 years. He is board-certified by American Board of Psychiatry & Neurology and a member of the American Academy of Neurology.

After studies in Mechanical and Environmental Engineering at Bucknell (Lewisburg, PA) and Cornell (Ithaca, NY) Universities, he worked for a period in industry as supervising engineer. He then attended Columbia University in New York City for premedical studies, followed by medical school at the University of Texas Southwestern Medical School, Dallas, TX. Residencies in neurology and

neurosurgery were at the University of Florida, Gainesville, FL. Additional studies included a medical student fellowship in cardiology at Radcliffe Infirmary, Oxford and clinical neurology postgraduate fellowship at National Hospital for Nervous Disease, Queen Square, London, UK.

Through his affiliation with Lovelace Scientific Resources, Inc., Albuquerque, NM and his own clinical practice, he has participated in over 60 pharmaceutical industry-sponsored clinical trials. He currently functions as Principal Investigator in a number of ongoing drug research studies in MS, epilepsy, pain, Parkinson’s disease, and other neurological diseases.

Dr. Aung-Din is also active in treating varied neurological and psychiatric conditions using delivery of CNS-active drugs with Direct Effects topical delivery, a technology developed by him for which 7 patents have to date been granted in the United States, Europe, and Australia; with others pending.

Publications using this novel therapy in migraine, Parkinson’s disease, and diabetic neuropathy appeared in Drug Delivery Technology, Vol.10. No 8, p. 48, October 2010 and Drug Delivery Technology, Vol. 9. No 9, p. 44, October 2009, www.drugdeliverytech.com; and in June 2015 www.drug-dev.com: “THERAPEUTIC FOCUS – Direct Effects(TM) Diabetic Neuropathy Therapy: Treating Symptoms & Modifying Disease.”

Direct Effects topical drug delivery is unique in that therapeutic effect occurs through cutaneous free-nerve endings with direct afferent connections to CNS. As such, general circulation and blood-brain-barrier are bypassed, with avoidance of systemic side effects and drug interactions. AfGin Pharma, LLC was founded by Dr. Aung-Din in 2009 to advance this unique technology and its goal of “Enhanced Neuro-Therapeutics through Direct Effects Topical Technology;” website: www.afginpharma.com.